(Reuters) – AstraZeneca said on Thursday a late-stage trial of its medicine for a rare disease that causes accumulation of copper in the body was three times more successful in helping remove deposits from tissues as compared with standard care.
The drug, developed by the drugmaker’s Alexion rare diseases unit, was being tested for Wilson disease, a genetic condition in which the body’s ability to remove excess copper is compromised.
(Reporting by Pushkala Aripaka in Bengaluru, Editing by Sherry Jacob-Phillips)
